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Chronic epilepsyd biochemical aspects of mitochondrial bioenergetics dysfunction in hereditary
neurological disorders associated with complex I defects. Three types of hereditary complex I dysfunction are
dealt with: (i) homozygous mutations in the nuclear genes NDUFS1 and NDUFS4 of complex I, associated
with mitochondrial encephalopathy; (ii) a recessive hereditary epileptic neurological disorder associated
with enhanced proteolytic degradation of complex I; (iii) homoplasmic mutations in the ND5 and ND6
mitochondrial genes of the complex, cohexistent with mutation in the nuclear PINK1 gene in familial
Parkinsonism. The genetic and biochemical data examined highlight different mechanisms by which
mitochondrial bioenergetics is altered in these hereditary defects of complex I. This knowledge, besides
clarifying molecular aspects of the pathogenesis of hereditary diseases, can also provide hints for under-
standing the involvement of complex I in sporadic neurological disorders and aging, as well as for developing
therapeutical strategies.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionDysfunctions of complex I of the respiratory chain encompass
more than 30% of hereditary mitochondrial encephalopathies [1–3].
Complex I defects have also been observed in other neurological dis-
orders [4,5], like sporadic [4,5] and familiar Parkinson disease (PD)
[6,7], hereditary spastic paraplegia [8], Friedreich Ataxia [4], as well as
in aging [9,10]. Once the genetic basis of hereditary complex I deﬁ-
ciencies has been deﬁned, much more work is needed to under-
stand, as in the case of many other hereditary diseases, the pathways
going from the mutated gene to the biochemical, cellular, tissue
disorder and ultimately to the clinical course of the disease. Clari-
ﬁcation of this issue represents today a major challenge in biomedical
research.
Complex I is the largest enzyme of the mammalian oxidative
phosphorylation system. With a molecular weight of ∼1·106 Da ithemistry, Biology and Physics,
541; fax: +39 080 5448538.
a).
ll rights reserved.contains a series of redox centers (one FMN, seven FeS-centers and
two protein bound semiquinone/quinol couples) which catalyze
the stepwise transfer of electrons from NADH to ubiquinone of the
pool, coupled to the translocation of 4H+/2e− from the mitochond-
rial matrix to the cytosol [11–19] (Fig. 1). Complex I is made up of
45 protein subunits [20], of which seven are encoded by the
mitochondrial genome, the others by nuclear genes [17,21]. Four-
teen conserved subunits are essential for the redox and proton
pumping activity [11,17]. Some of the supernumerary subunits
participate in the assembly of the complex [22–25], others appear to
be involved in regulatory function [17,25–28]. Complex I is a regul-
able pacemaker of the mitochondrial respiratory function [25–28],
is a major site of cellular oxygen superoxide production [11,25,29–
33] and is involved in apoptosis [34–36] and age-related functional
decline [9,10].
The functional level of complex I in mammalian cells depends on:
(i) coordinated expression of nuclear and mitochondrial genes; (ii)
post-translational subunit modiﬁcation; (iii) mitochondrial import/
maturation of nuclear encoded subunits; (iv) subunits interaction and
stepwise assembly; (v) proteolytic processing.
Fig. 1. Shape and electron and proton transfer pathways in complex I. The shape was obtained from high resolution electron microscopy image reconstitution of N. crassa complex I
[15]. The location of the redox centers [12,16] is obtained from the X-ray crystallographic structure of the hydrophilic moiety of the T. thermophilus complex I (see Ref. [16]). In yellow
a tentative ubiquinone-gated proton pump mechanism is shown [18], which translocates 4H+ from the matrix space to the cytosol per two electrons ﬂowing from NADH2 to
ubiquinone of the pool. In this model cooperative redox-linked H+ transfer by the N2-PSST subunit mediates proton consumption from the N space in the reduction of a protein
stabilized UQ
U− to UQH2 (UQNFU− in Ref. [19]). Protons are then released toward the P space upon electron transfer from this UQH2 to a protein stabilized UQ/UQU− couple (in black)
acting as electron transfer center (QNS in Ref. [19]) and from this to the ubiquinone of the pool [18,25].
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mechanisms in three types of hereditary dysfunctions of complex I
in neurological diseases: (i) homozygous mutations in the nuclear
genes NDUFS1 and NDUFS4, encoding for two structural subunits of
complex I, both associated with mitochondrial encephalopathy; (ii) a
recessive hereditary epileptic neurological disorder associated with
enhanced proteolytic degradation of complex I; (iii) homoplasmic
mutations in the ND5 and ND6 mitochondrial gene of the complex,
cohexistent with mutation in the nuclear PINK1 gene in a familial
case of PD.
2. Homozygous mutations in NDUFS1 and NDUFS4 genes of
complex I in mitochondrial encephalopathy
Papa et al. [22,37–39] have studied the impact on mitochondrial
functions of mutations in the nuclear NDUFS4 and NDUFS1 genes of
complex I, in children affected by neurological disease.
The 18 kDa (AQDQ) subunit [20,21], encoded by the NDUFS4 gene,
is essential for the assembly of the complex [22,23]. It is phosphory-
lated in murine [40,41] and human [22,37] cell cultures “in vivo”, by
the cAMP-dependent protein kinase A, this phosphorylation being
apparently involved in activation of the NADH-ubiquinone oxidor-
eductase activity of the complex [22,37,40,41] and prevention of
accumulation of oxygen free radicals [25,42].
Import in mitochondria of the NDUFS4 precursor protein, with the
N-terminal mitochondrial targeting sequence, expressed “in vitro” in
a reticulocyte lysate [43,44], or “in vivo” in transfected Hela cells [44],
and its cleavage to the mature form, is promoted by phosphorylation
of the protein by PKA [44]. In ﬁbroblasts from control subjects and a
neurological patient, with mutation in the NDUFS4 gene resulting in
disappearance of the 18 kDa (AQDQ) subunit, the newly imported
protein was assembled in complex I [43]. These ﬁndings shed lighton the mechanism by which PKA mediated phosphorylation of the
NDUFS4 subunit can result in promotion in cell cultures “in vivo” of
the NADH-ubiquinone oxidoreductase activity of the complex. It is
not clear whether the NDUFS4 subunit is assembled in the complex
in the phosphorylated or dephosphorylated form. In the inner
mitochondrial compartment a phosphatase activity, which depho-
sphorylates the NDUFS4 protein has, in fact, been detected [45].
These observations could explain negative results of attempts to
detect the phosphorylated form of the 18 kDa (AQDQ) protein [46] in
complex I in isolated bovine heart mitochondria and the puriﬁed
complex [47]. For a more detailed discussion of this issue see, how-
ever Ref. [25].
Four pathological exonic mutations [38,48,49], one intronic muta-
tion [50], and a deletion of exons 3 and 5 [51] in the NDUFS4 gene [52]
have been found in different neurological patients (Fig. 2). The im-
pact on mitochondrial functions of three of these mutations in the
coding sequence of the NDUFS4 gene has been characterized: a base
duplication at position 466–470 in exon 5, which destroyed the RVS
phosphorylation site in the carboxy terminus [48], a single base dele-
tion at position 289/290 in exon 3, introducing a premature termi-
nation codon (PTC) [49] and a nonsense mutation in the ﬁrst exon
causing premature termination after only 14 aminoacid residues of
the protein [38] (Fig. 2). Not only in this last mutation, as expected, but
also in the other two the entire 18 kDa (AQDAQ) subunit disappeared
from the patient's ﬁbroblasts [22]. All the three NDUFS4 muta-
tions resulted in defective assembly of complex I, with the appearance
of a non-functional lower molecular weight subcomplex (Fig. 3, [22])
and complete suppression of the NADH-ubiquinone oxidoreduct-
ase activity which did not respond any longer to cAMP activation
(Fig. 4, [22]).
The 75 kDa-FeS protein encoded by the NDUFS1 gene is the largest
conserved subunit of complex I, which contains the N1b, N4, N5 Fe–S
Fig. 3. Two dimensional electrophoretic pattern of respiratory complexes (I, III and IV) and ATP synthase complex (V) in mitoplasts from control (NHDF) and patient's ﬁbroblasts. The
complexes were separated by Blue Native electrophoresis and resolved in their subunits in a second dimension SDS-PAGE. Subunits were detected with speciﬁc antibodies. For details
see text and Ref. [39] from which the ﬁgure is reproduced with permission.
Fig. 2. Structure of the NDUFS4 human gene of complex I with location of mutations found in neurological patients with complex I deﬁciency. In the table the four exonic mutations,
the intronic mutation shown in the structure of the gene (A) and a sixth mutationwith deletion of a region including exons 3 and 5, with the associated diseases are listed. For details
see text, Ref. [52] and the references in the table.
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Fig. 4. NADH-ubiquinone oxidoreductase activity of complex I in mitoplasts from
control (NHDF) and patient's ﬁbroblasts. Effect of dibutyryl-cAMP. The speciﬁc
enzymatic activities (Vmax) were corrected for the rotenone insensitive reaction.
Where indicated the ﬁbroblast cultures were exposed to 100 μM dibutyryl-cAMP for
60 min. Data from Refs. [37–39]. For details see Refs. [37–39] and text.
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and 5). Large scale deletions and point mutations in the NDUFS1 gene
have been found in patients with mitochondrial encephalopathy [53].
Iuso et al. [39] have characterized the functional consequences of a
C1564A homozygous mutation in the NDUFS1 gene (Q522K replace-
ment in the 75 kDa protein) in a child affected by progressive
leukodystrophy [3]. Glutamine 522 of the human protein is replaced
by asparagine in the corresponding subunit (NqO3 gene) of the Ther-
mus thermophilus complex I. The X-ray crystallographic structure ofFig. 5. X-ray crystallographic structure of the NqO3 subunit of T. thermophilus complex I (ho
cluster associated to the subunit and the aminoacid sequence of subdomain IV of the c-termin
the NDUFS1 C1564A mutation, is shown in red. In red the homologous asparagine in the Nthe bacterial complex I [16] showed that this asparagine is located in
subdomain IV of the C-terminal part, which undergoes conforma-
tional change to an open conﬁguration upon reduction of the complex
by NADH (Fig. 5) [16].
In the ﬁbroblasts of the patient harbouring the C1564A muta-
tion the content of the mitochondrial normally assembled complex
decreased signiﬁcantly as compared to normal cells and a lower
molecular mass of the complex appeared (Fig. 3) [39]. The muta-
tion resulted also in a marked, but not complete, suppression of the
NADH-ubiquinone oxidoreductase activity (Fig. 4) and depression of
the mitochondrial membrane potential [39]. In the ﬁbroblasts with
the NDUFS1 mutation, but not in those with the NDUFS4 mutation,
there was a large accumulation of H2O2 and intramitochondrial O2
U−
(Fig. 6).
Complex I is generally considered to represent the major mito-
chondrial source of O2
U− in mammalian cells [29–33]. The complete
suppression of the normal rotenone-sensitive NADH-ubiquinone
oxidoreductase, caused by the deletion of the NDUFS4 encoded
18 kDa subunit, is likely to result from inhibition of a redox step that is
also involved in the direct reduction of O2 to O2
U− [30–33]. In the case
of the NDUFS1 mutation, the inhibition of the NADH-ubiquinone
oxidoreductase can be attributed to altered function of the 75 kDa
Fe–S protein encoded by this gene. The Q522K substitution can pro-
mote direct oxidation by molecular oxygen of the NDUFS1 Fe–S
center(s) or of other redox centers on the substrate side, once they are
reduced by NADH.
In the NDUFS1 mutant the depression of the activity of complex I
(Fig. 4) and of the membrane potential [39] was counteracted by the
addition to the ﬁbroblasts culture of dibutyryl-cAMP, which also
prevented the accumulation of oxygen free radicals [39]. Both these
rescue effects of cAMP have been generally observed in a variety of
human and murine cell cultures, under conditions in which themologous of the human NDUFS1, 75 kDa FeS subunit). Redrawn from Ref. [16]. The FeS
al part of the NqO3 and NDUFS1 proteins are presented. The Gln 522, replaced by Lys in
qO3 corresponding region is also shown.
Fig. 6. Laser scanning confocal images of H2O2 and O2
U− levels in control (NHDF) and patient's ﬁbroblasts. H2O2 was detected by the green ﬂuorescence of DCF; mitotracker red
ﬂuorescence detected mitochondrial membrane potential; mitosox red ﬂuorescence detected intra-mitochondrial O2
U− Reproduced with permission from Ref. [39]. For details see
Ref. [39] and text.
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systems [25,42, see also 32].
A study of the NDUFS4 transcripts in the ﬁbroblasts from three
patients harbouring three different mutations in the gene re-
vealed new aspects of the transcription of this gene (Fig. 7). The ﬁve
exons of the gene result in a canonical mRNA coding for 175 residue
protein (the precursor of the 18 kDa (AQDQ) subunit of complex I)
[22]. In the patient with the point deletion at position 289/290 in
exon 3 the transcript level was much reduced as compared to
control cells [22] (Fig. 7). The introduction of the PTC in the middle
of the transcript elicited its degradation by non sense mediated
decay (NMD) [22] a mechanism of quality control that ensures
ﬁdelity of gene expression [54]. This explains the disappearance
of the 18 kDa (AQDQ) protein from the patient's cells [22]. In the
case of the 5 bp duplication at position 466/470 in the ﬁfth-exon
the transcript level was normal (Fig. 7) [22]. In this case the dis-
appearance of the overall protein could be due to defective trans-
lation of the mutated transcript and/or proteolytic degradation of
the longer translated product. In the 44G→A non sense mutation in
the ﬁrst exon, disappearance of the mature protein was expected.
This mutation which introduced a PTC in the proximity of the
canonical AUG start codon, rather than eliciting NMD degradation
of the canonical mRNA, upregulated three PTC containing alter-
native transcripts [55,56] (Fig. 8). The splice variants 1 and 2 (SV1
and SV2) result from insertion between exons 2 and 3 of a
cryptoexon which uses two alternative acceptor sites (Fig. 8). The
splice variant 3 (SV3) derives from exon 2 skipping [55,56]. These
three alternative transcripts are produced also in normal cells buttheir level is kept low by RNA surveillance mechanisms. SV1 and
SV2 are degraded in the cytosol by NMD, the level of SV3 is down-
regulated directly in the nucleus [56]. The 44 G→A non sense
mutation inactivated in the patient ﬁbroblasts NMD degradation of
SV1 and SV2 and nuclear down regulation of SV3 (Fig. 8) [56]. In a
neurological patient with a homozygous splice acceptor site muta-
tion in intron 1 (IV Snt-1, G→A) of the NDUFS4 gene (Fig. 9) only a
mRNA transcript, in which exon 2 was skipped, was detected [50].
Ampliﬁcation of this transcript and sequencing showed that it
corresponded exactly to the PTC containing SV3 isoform detected
in the patient with G44A nonsense exonic mutation in the NDUFS4
gene (Fig. 9) [56]. The accumulation of the aberrant alternative
transcripts, caused by the exonic or the intronic mutation in the
NDUFS4 gene, can represent another deleterious event contributing
to the pathogenetic mechanism of the mutations in neurological
patients.
In summary the NDUFS4 mutations, which were associated with
earlier onset and severe disease course resulted in: (i) disappearance
of the 18 kDa (AQDQ) protein it encodes; (ii) block of the last step in
the assembly of the complex; (iii) full suppression of the NADH-
ubiquinone oxidoreductase activity; (iv) loss of cAMP promotion of
the activity; (v) loss of Pasteur effect with enhanced glycolitic activity
and chronic lactic acidosis; (vi) accumulation of unproductive
alternative transcripts of the gene [22,50,55,56].
The C1564A NDUFS1 mutation, which was associated with a less
severe disease, did not suppress completely the NADH-ubiquinone
oxidoreductase activity of the complex. The decrease of the level
of mature complex I, could be due to proteolytic degradation of
Fig. 7. Structure of normal NDUFS4 mRNA and mRNAs generated by the NDUFS4 pathological alleles and their steady-state levels in ﬁbroblasts cultures. (A) In the G44A
mutation as well as in the 289/290G deletion the aminoacids 15 and 96 change respectively from a tryptophan to a stop codon; the AAGTC 466–470 Dupl caused a frame shift
with 14 aminoacids elongation of the protein (in black) and disrupted the phosphorylation site (RVS 129–131). (B) Northern blots (on the left) of total RNA from ﬁbroblasts of a
healthy child as control and patients with AAGTC 466–470 Dupl, 289DelG, and G44A, hybridized with a radiolabelled NDUFS4 cDNA region. A β-actin probe estimated the
amount of loaded RNA. Real time PCR (on the right) of total RNA from ﬁbroblasts of a control, AAGTC 466–470 Dupl, 289DelG, and G44A patients. The relative expression levels
of the NDUFS4 transcripts with respect to the GAPDH transcript, used as internal reference, are presented. The experimental data in (B) are reproduced with permission from
Ref. [22]. For details see text.
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Q522K replacement in the 75 kDa protein could alter the redox
function of the FeS centers (N1b, N4, N5) in this subunit and/or
other redox components, resulting in inhibition of the normal for-
ward electron transfer activity and enhanced direct reduction of O2
to O2
U−.
3. Proteolytic degradation of complex I in a progressive hereditary
epilepsy
Mutational gene analysis and cellular biochemical investiga-
tions carried out in our laboratories on two male sibs, affected
recessively by inherited progressive cerebral atrophy, lactic acidosis
and drug resistant epilepsy, reveal a new type of hereditary patho-
logical dysfunction of complex I. Primary ﬁbroblast cultures of both
children exhibited a deﬁnite decline of the NADH-ubiquinone
oxidoreductase, more severe in one of the two patients (Fig. 10A).
This was reﬂected in a lower mitochondrial content of complex I,
as shown by decreased level of the mitochondrial encoded ND6
and the nuclear encoded NDUFA9 and NDUFB6 subunits (Fig. 10B).The activity and content of cytochrome c oxidase and complex V
(ATP synthase) subunits were, on the other hand, normal. Diffe-
rently from what observed in the mutations of the NDUFS1 and
NDUFS4 gene of complex I no lower molecular form of complex I was
detectable.
Extensive mutational analysis did not show any pathogenetic
mutation in the seven mitochondrial genes and 38 nuclear genes of
complex I, except homozygous or heterozygous substitutions already
reported in EST (Expressed Sequence Tags) data banks and ANP
(single nucleotide polymorphisms) (http://www.ensembl.org).
The addition to the patient's ﬁbroblast culture of a cocktail of
protease inhibitors did rescue the level of subunits of complex I and
the NADH-ubiquinone oxidoreductase activity (Fig. 10). No effect of
the protease inhibitors was exerted on the subunit level and activity of
cytochrome c oxidase and complex V.
Analysis of the import of the NDUFS4 precursor protein in
mitochondria isolated from ﬁbroblasts of the two children shows
that, whilst the binding of the precursor at the organelle surface was
only partially decreased, the mature form of the imported protein,
detected in the mitochondria from control ﬁbroblasts, disappeared in
Fig. 8. Impact of the exonic G44A mutation on the expression of the NDUFS4 gene. (A) The scheme shows the mechanism of production of the alternative splicing products (B)
normally produced by the NDUFS4 gene but up-regulated in the G44A mutation ﬁbroblasts. (B) RT-PCR performed using two primers encompassing all the NDUFS4 ORF. (C) Real-
time PCR in total RNA from ﬁbroblasts of a control and G44A patient. The relative expression levels of the NDUFS4 alternative transcripts as well as the canonical mRNAwith respect to
the GAPDH transcript, used as internal reference, are presented. Reproduced with permission from Refs. [55,56].
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form of the NDUFS4 protein was again detectable in the patient's
mitochondria, when the import assay was carried out in the presence
of protease inhibitors (Fig. 11).
The above results indicate that the decreased content of func-
tional complex I in the patient's ﬁbroblasts is due to digestion of the
complex by a protease present in the intra-mitochondrial space. It has
been reported that calpain 10, a member of a family of 14 cysteine
proteases, is localized in mitochondria and its activation by Ca2+
results in digestion of complex I subunits, including the mitochondrial
encoded ND6 [57]. Preliminary confocal microscopy analysis of
calpain activity based on the ﬂuorescence of the cleavage product of
the substrate SLLVY-AMC [57], revealed enhanced activity of the
enzyme in both patient's ﬁbroblasts, apparently colocalized with
mitochondria (results not shown). Further work is in progress in our
laboratories to identify the genetic factors involved in the activation of
the proteolytic activity.
4. Homoplasmic mutations in the ND5 and ND6 mitochondrial
genes of complex I in PINK1 familial Parkinsonism
Whilst the cause of sporadic PD remains unclear, several genes
have been identiﬁed as responsible for hereditary forms of PD
[4,58–60]. Mutations in the phosphatase and tensin homolog
(PTEN) induced serine/threonine putative kinase-1 (PINK1) gene(Fig. 12) represent the second most common cause of autosomal
recessive Parkinsonism (ARP) [61,62].
Recent work from different groups provides converging evidence
showing that the [8] PINK1 kinase is involved in the degradation of
unfolded or oxidized mitochondrial proteins [63–65], autophagy of
damaged mitochondria [66–69] and mitochondrial ﬁssion/fusion [70].
PINK1 with an N-terminal mitochondrial targeting sequence is
essentially localized in mitochondria. It has been reported from time
to time that PINK1 is associated with the inner membrane [63,64,71],
the intermembrane space [64,65,71] and the outer membrane [72]. The
catalytic domain of the outermembrane PINK1 faces the cytosolic space
[72] where it phosphorylates the E3 ubiquitin ligase parkin [67,73],
product of the PARK2 gene, whose mutations represent the ﬁrst most
common cause of autosomal recessive Parkinsonism [74]. Parkin
phosphorylation promotes its translocation from cytosol to mitochon-
dria [73], where it participates to autophagy of damaged mitochondria
[66–69]. PINK1 has also been reported to phosphorylate TRAP1
(HSP75) [64] and to regulate, through an indirect phosphorylation
mechanism, the protease HtrA2 [65], both these proteins being
involved in quality control of oxidized mitochondrial proteins. Since
TRAP1 and HtrA2 reside in the intramitochondrial space it is possible
that PINK1 canpartition between the outer and the innermitochondrial
location in response to the prevailing cellular conditions [see also 75].
Different mutations in the PINK-1 gene have been detected in ARP
and PD cases with an early onset [61,76–78] (Fig. 12). Even if the
Fig. 9. Impact of the intronic IVS1nt-1,G-A mutation on the expression of the NDUFS4 gene. (A) The scheme shows the only splicing product generated by the IVS1nt-1,G-A mutated
NDUFS4 gene. (B) Real-time PCR of total RNA from ﬁbroblasts of a control and the IVS1nt-1,G-A patient. The relative expression level of the NDUFS4 transcripts with respect to the
GAPDH transcript, used as internal reference, is presented. Reproduced with permission from Ref. [56].
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generally evolve towards the disease, in some cases it does albeit with
a later onset [78,79]. This would suggest that dysfunction of PINK1
may promote the disease in combination with other acquired or
inherited defect(s). Mutations in mitochondrial DNA have, on the
other hand, been reported in PD [67,80]. Our group has characterized
the mitochondrial genotype and function in a female patient carrying
a homozygous W437X PINK-1 mutation [6,7], resulting in a C-
terminus truncated kinase with depressed kinase activity (Fig. 12)
[81]. The samemutationwas present in the heterozygous state in both
the patient's parents [7] (see Fig. 12C). The ﬁbroblasts of the
homozygous W437X patient showed a signiﬁcant depression of the
oligomycin sensitive, endogenous respiratory activity both in the
coupled and CCCP-uncoupled state, accounting in the last case for 50%
depression as compared to control value (Fig. 13A). The respiratory
control ratio was also lower. Direct enzymatic assays showed in the
patient's ﬁbroblasts normal speciﬁc activities of complex I and III of
the respiratory chain (Fig. 13B). The speciﬁc activity of complex IV was
also normal when assayed with added cytochrome c (a), but
depressed when assayed with ascorbate plus TMPD (b), a condition
that depends on the endogenous mitochondrial content of cyto-
chrome c (Fig. 13B). The cellular level of ATP was higher in patient's
ﬁbroblasts than in controls when cells were grown in a glucose
medium, but signiﬁcantly lower in a galactose medium (Fig. 13C), a
condition in which ATP is essentially produced by mitochondrial
oxidative phosphorylation [82].
Two dimensional blue-native/SDS gel-electrophoresis combined
with immunoblotting detection of constituent subunits of oxidative
phosphorylation complexes showed no signiﬁcant change in the
content and subunit pattern of complexes I, III, IV and V (F0F1 ATP-
synthase) in the patient's ﬁbroblasts as compared to control [6,7].
Analysis with a speciﬁc ﬂuorescent antibody showed that the
content of cytochrome c, whose cellular distribution in control ﬁbro-
blasts mimicked the mitochondrial reticular network, was markedly
reduced in the patient's ﬁbroblasts (Fig. 14A). Similar analysis
with speciﬁc ﬂuorescent antibodies showed that in the patient'sﬁbroblasts there was no decrease in the level of the mitochon-
drial β-subunit of the ATP synthase and subunit IV of complex IV
(Fig. 14A) [6].
Confocal microscopy analysis with ﬂuorescent probes revealed in
patient's ﬁbroblasts signiﬁcant accumulation of H2O2 with a reticular
distribution resembling the mitochondrial network (Fig. 14B). The
MitoSox probe, which accumulates in mitochondria and reacts
speciﬁcally with O2
U−, revealed accumulation of this oxygen reactive
species in patient's mitochondria [7]. The accumulation of H2O2 in
patient's ﬁbroblasts was not prevented by apocynin, which speciﬁcally
inhibits the plasma membrane NADPH oxidase [83] neither by
dibutyryl-cAMP. On the contrary DPI, which binds irreversibly to the
prosthetic ﬂavin moiety of redox enzymes, including complex I [84],
prevented completely the accumulation of H2O2 in the patient's
ﬁbroblasts (Fig. 14B). The accumulation of ROS in patient's ﬁbroblasts
was not due to a deﬁciency of the ROS scavenger capacity [6]. The
depressed production of ATP by mitochondrial oxidative phosphor-
ylation and the concomitant ROS accumulation, detected in the
patient's ﬁbroblasts could both result from the combined impact of
complex I dysfunction, caused by a ND6mutation [7] (see below), and
the decreased mitochondrial content of cytochrome c [6]. The PINK-1
mutation can be responsible for this decrease of mitochondrial
cytochrome c content. Defective phosphorylation by the mutated
PINK1 kinase activity of TRAP1 has been reported to abrogate a
protective effect exerted by this chaperon protein in preventing
cytochrome c release from mitochondria [64].
Quantitative PCR showed that normal and patient's ﬁbroblasts had
a comparable content of mtDNA amounting to around 1000 mtDNA
copy number/cell [7]. Sequence analysis of mtDNA of the homozygous
patient's ﬁbroblasts showed a number of single nucleotide changes
(SNCs) disseminated throughout the entire mtDNA (Fig. 15) [7]. All
but two were already reported as known polymorphisms (http://
www.mitomap.org). These two SNCs were m.A12397G and m.T14319.
C in the ND5 and ND6 genes, respectively. Notably, both were
homoplasmic [7] and conﬁrmed in DNA extracted from the patient's
blood. Both the ND5 and ND6 mutations were also found in the
Fig. 10. Enzymatic activities of complexes I, IV and V and subunit levels of complexes I, III and IV in mitoplasts from control and progressive hereditary epilepsy patient's (K and C)
ﬁbroblasts, before and after treatment with protease inhibitors (IP). Where indicated ﬁbroblast cultures were treated for 48 h with the protease inhibitors cocktail (SIGMA) at 1:400
dilution (dissolved in DMSO and containing aprotinin, bestatin, leupeptin, pepstatin A and E-64 which is, in particular, speciﬁc for calpains). Panel A: Enzymatic activities, means±
standard error of 3 or more determinations. NADH-UQ oxidoreductase activity was measured as described in [22]; cytochrome c oxidase activity was determined as in [39] and ATP
hydrolase activity as in [7]. Panel B: Immunoblot and relative densitometric units of complexes I, III and IV subunits. Two-dimensional gel analysis (Blue Native PAGE/SDS-PAGE) of
the mitoplasts and immunoblotting were carried out as in Ref. [39]. Monoclonal antibodies against subunits of complex I (NDUFA9, ND6, NDUFB6), the core II subunit of complex III
and the subunit IV of complex IV were from Molecular Probes (Invitrogen). Detection by chemiluminescence reaction was carried out by using the Western Lightning
Chemiluminescence Reagent Plus, followed by exposure to Hyperﬁlm (Amersham Pharmacia). Quantiﬁcation was made by densitometric analyses of bands intensity (VersaDoc
Imaging System model 1000-Bio-Rad).
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Conversely, the same analysis carried out on the patient's father blood
resulted in a normal ND5 and ND6 genotype [7]. The mother
presented a late onset PD, the father at the age of 70 was still exempt
from the disease (see Fig. 12C). Collectively these results demonstrate
that the homoplasmic mtDNA mutations found in the patient
cohexisted with the PINK1 mutation at birth and were inherited by
the mother, which carried the same homoplasmic mtDNA mutations.
ND5 and ND6 are two of the seven mtDNA encoded, membrane
embedded, subunits of complex I. Themt A12397Gmissensemutation
changes a threonine in alanine at position 21 of the ND5 subunit (in a
hydrophilic segment likely exposed to the inter-membrane mitochon-
drial space) [7]. Various ND6 mutations leading to aminoacid changes
have been found, associated with mitochondrial diseases [85,86] and
tumour cell metastasis [87]. Some of thesemutations result in changes
in the kinetics parameters of complex I [85,86] and/or production of
oxygen free radicals [87,88] (see Fig. 16). Site directed mutagenesis in
the NuoJ subunit (counterpart of the mammalian ND6) of E. coli
complex I resulted in suppression of the proton pumping activity of
the complex [89]. Similar site-directed mutagenesis indicated that
the NuoJ subunit also delineates the binding site of ubiquinone [90].
In both cases [89,90] the assembly of complex I and its speciﬁc
oxidoreductase activity were unaffected by the mutations as, in fact,
found in the mitochondria from the patient of our study. The mt
T14319C mutation changes an asparagine in aspartic acid at position
119 of the ND6 subunit. This mutation is located in the ﬁfth of six
predicted transmembrane helices (TMH) [7]. A comparison of thehydropathy plot between the ND6 wild-type and the N119D mutant
resulted for the latter in a pronounced destabilizing effect of the
TMH-V [7]. Enzyme kinetic analysis of the NADH-ubiquinone oxi-
doreductase activity of complex I in normal and patient's ﬁbro-
blasts showed an almost ﬁvefold decrease of the apparent Km for
both ubiquinone and NADH in the patient's sample [7]. Conversely,
the estimated maximal rate of complex I was practically unchanged
when ubiquinone was used as limiting substrate, whereas a 26%
inhibition of the Vmax was observed in patient's ﬁbroblasts titrated
with NADH [7].
The changes in the Km of the substrates in the patient's NADH:
ubiquinone oxidoreductase activity would argue in favour of altera-
tion in the catalytic feature of the enzyme. This, without compromis-
ing the overall electron transfer in the mitochondrial respiratory
chain, may be, nevertheless, responsible for the enhanced production
of ROS [see also Refs. 87,88]. The higher afﬁnity for ubiquinone of the
patient's complex I could predispose to a longer occupancy of the
reduced quinone or of the semiquinone radical species at the catalytic
site(s), with altered reduction potential of the upstream redox centers.
It can be recalled here that exposure of rats to complex I inhibitors
like rotenone and 1-methyl-4-phenylpyridinium (MPP+) causes
oxidative stress and reproduces features of PD [91,92]. It has, also,
been reported that the anti-apoptotic proteolytic activity of HtrA2,
downregulated in PINK1-mutated PD patients [65], is enhanced [93]
by interaction with the protein product of GRIM19 gene (cell death
regulatory gene induced by interferon and retinoic acid) [34]. The
protein product of GRIM-19 has been identiﬁed as a subunit of
Fig. 12. Structure of the gene (A) coding for the PTEN induced kinase 1 (PINK1) protein (B) localized in the inner mitochondrial membrane. In B, the domains of the PINK1 protein
(from ExPASy Proteomics Server; http://www.expasy.org/) and the mutations found in patients with familiar Parkinson are shown. (C) PINK1 G1311A (W437X) mutation in the
alleles and ND5 and ND6 mutations in the patient studied and her parents. Onset age of the clinical manifestations of the disease is also shown.
Fig. 11. Import of [35S]Met-labelled NDUFS4 protein in mitochondria isolated from human cell cultures. In vitro transcription and translation of radiolabelled [35S] methionine
NDUFS4 precursor protein were performed in Rabbit Reticulocyte Lysate System (RRL). Mitochondria were isolated from control and patients ﬁbroblasts. Cells were collected by
centrifugation at 500 g for 3′ and homogenized in ice-cold homogenization buffer (300 mM sucrose, 1 mM EGTA, and 20 mMMOPS, pH 7.4). Nuclei and cellular debris were pelleted
by centrifugation at 600 g for 15min. The supernatant was centrifuged at 10,000 g for 25min, resulting in a crudemitochondrial pellet. Mitochondriawere immediately employed for
import experiments. Panel A, RRL translation product were incubatedwith freshly isolatedmitochondria, from control (lanes 1) or from ﬁbroblasts from patient K (lanes 2) or patient
C (lanes 3), in BSA buffer (20 mMHEPES-KOH pH 7.4, 250 mM sucrose, 80 mM potassium acetate, 5 mMmagnesium acetate, BSA 3%) plus 10 mM sodium succinate and 2 mMATP at
for 90min. at 37 °C. Mitochondriawere spun down from the import mixture before or after trypsin treatment (0.5 μg per 50 μgmitochondrial proteins, 35min on ice). The solubilized
pellets were analyzed by SDS-PAGE and autoradiography. Panel B, RRL translation product were incubated with freshly isolated mitochondria, from control ﬁbroblasts (lane 1),
ﬁbroblasts from patient K (lane 2) or from patient C (lane 3), as described above, in the presence of protease inhibitors cocktail (dilution 1:600). Aliquots of the all samples were
subjected to western blotting with antibody against the core II subunit of bc1 complex for other experimental details see Ref. [44].
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Fig. 13. Functional pattern of the oxidative phosphorylation system in control ﬁbroblasts (NHDF) and ﬁbroblasts from the Parkinson patients with the homozygous G1311A mutation
in PINK1. (A) Endogenous respiration rate in the absence or presence of oligomycin (state 4) or of the uncoupler CCCP, RCR, respiratory control ratio. (B) Speciﬁc enzymatic activity of
complexes I, III and IV (a, with added cytochrome c; b, supported by ascorbate plus TMPD). (C) ATPase activity of complex V and ATP content in ﬁbroblast cultures grown in glucose or
galactose medium. Reproduced with permission from Ref. [6]. For details see Ref. [6] and text.
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for the assembly/function of the complex [94]. This intriguing PINK1/
HtrA2/complex I interaction seems to deserve further study. It has, for
example, been found that all-trans retinoic acid increases, by a post-
transcriptional mechanism, the mitochondrial level of the protein
product of GRIM-19 in complex I [95]. It would be of interest to
investigate whether this effect of retinoic acid, which resulted, how-
ever, in a marked inhibition of the NADH-ubiquinone oxidoreductase
activity [95], is associated with the reported stimulation by retinoic
acid of protein phosphatase activity [96,97].
What presented provides an in sight into the possible combined
impact of PINK1 and mtDNA mutations in the development ofParkinsonism, as exempliﬁed by the familial case examined (see Fig.
12). In addition to the germinal ones present at birth, mutations in
mitochondrial genes of complex I, i, can accumulate in the life span, in
particular with aging. This can result per se in general decline of the
functional capacity of oxidative phosphorylation complexes [9,10,98].
Complex I due to its gene and protein complexity appears to be an
hotspot for gene mutations and protein damages.
The decline in the mitochondrial bioenergetics function, particu-
larly critical in neurons due to their high ATP demand [17], is normally
counteracted by defence mechanisms which encompass ROS scaven-
ger systems [33,42,99], quality control of DNA [100], RNA transcripts
[54,56] and oxidized proteins [63–65], autophagy of damaged
Fig. 14. Confocal microscopy analysis of cytochrome c content and H2O2 level in control (NHDF) and PINK1 mutant ﬁbroblasts. A): (a) Immunocytochemical detection of cytochrome
c in normal and patient's ﬁbroblasts was performed by binding of a secondary FITC-conjugated Ab to a primary mAb for cytochrome c. (b) Immunocytochemistry for detection of the
β-subunit of complex V and of subunit IV of cytochrome c oxidase (c) are also shown; in the latter a rhodamine-conjugated secondary Ab was used. B): H2O2 generation and
localization in control (NDHF) and patient's PINK1 mutated ﬁbroblasts. Fluorescence of the H2O2-probe DCF was visualised in live ﬁbroblasts by laser scanning confocal microscopy.
Reproduced with permission from Ref. [6]. See text and Ref. [6] for details.
513S. Papa et al. / Biochimica et Biophysica Acta 1787 (2009) 502–517organelles [66–68]. The PINK1 kinase, in combination with the
products of other genes like PARK2, DJ-1 [67,75,101], whose mutations
are associated with familial Parkinsonism, plays an essential role in
the quality control of altered mitochondrial systems.
In the family examined here the homozygous ND5 and ND6
mutations were both present in the patient's mother, heterozygous for
the PINK1 mutation. She presented a Parkinson syndrome in her
ﬁfties. Thus themtDNAmutation predisposed the PINK1 heterozygous
subject to a relatively late development of the disease (Fig. 12). In the
patient, the homozygous PINK1 mutation, impairing quality control
processes of damaged mitochondria, anticipated the decay of
mitochondrial functions associated with the cohexistent homoplas-
mic mutations in the ND5 and ND6 genes, with an early PD onset (age
22 years). The PINK1 heterozygous mutation, in the absence of ND5
and ND6 mutations, would not result in Parkinsonism, as the case of
the father still exempt from the disease in his seventies.
5. Conclusions
The genetic and biochemical observations examined in this paper
highlight different mechanisms by which genetic defects of complex Ialter the mitochondrial bioenergetics function in hereditary neurolo-
gical diseases. Mutations in the NDFUFS4 and NDUFS1 nuclear genes of
the complex are respectively associated with encephalopathy dis-
orders with different clinical features [3]. The NDUFS4 mutations
(18 kDa AQDQ subunit), which are most unfavourable, result in
disappearance of the subunit encoded by the gene, block of the last
step of the assembly of the complex, complete loss of the enzymatic
activity and its activation by cAMP, accumulation, for some of the
mutations, of unproductive alternative transcripts, severe chronic
lactic acidosis. These alterations underscore the fatal outcome of the
disease, whose conceivable treatment might rest on wild-type gene
transfection.
The NDUFS1 mutation (75 kDa FeS subunit), which is associated
with a less severe encephalopathy, results in marked but incomplete
depression of the content and enzymatic activity of complex I and
enhancement of ROS production, both these effects being reversed by
cAMP. Themature complex is converted to a small form, apparently by
proteolytic degradation promoted by the same ROS produced as a
consequence of the mutated 75 kDa subunit. In this case treatment
with β-adrenergic agonists and antioxidants could exert a beneﬁcial
effect on the clinical course of the disease.
Fig. 15. Results of the mutational analysis of the entire mtDNA of the Parkinson patient with homozygous G1311A mutation in the PINK1 gene. Reproduced with permission from Ref.
[7]. See text and Ref. [7] for details.
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lopathy, the deﬁcit of complex I appeared to be associated with a
genetically determined enhanced proteolytic degradation of the
complex by a mitochondrial protease, possibly of the calpain family.
The genetic determinants and the biochemical mechanisms leading toFig. 16. Localization of reportedmutations in the ND6 protein secondary structure. The secon
hydropathy plot. The model predicts six putative hydrophobic transmembrane helices, co
changes in aminoacid residues are reported with the respective references.this enhanced proteolytic activity remain to be elucidated. It might be
recalled, here, that in spastic paraplegia, loss of paraplegin, a putative
mitochondrial AAA protease, results, on the other hand, in defective
assembly of complex I and increased sensitivity to oxidative stress
[8,102]. Thus mitochondrial proteases can play a dual role in thedary structure andmembrane topology for the human ND6 proteinwas predicted by the
nnected each other by ﬁve loops (two external and three internal loops). Pathogenic
515S. Papa et al. / Biochimica et Biophysica Acta 1787 (2009) 502–517control of the functional level of complex I. Those like paraplegin
are essential for subunit maturation and assembly of the complex;
their mutational inactivation impairs formation of the mature com-
plex [102]. The second group of proteases, which appear to include
member(s) of the calpain family, are involved in the proteolytic
degradation of subunits of the complex [57]. Genetic factors leading to
anomalous enhancement of this proteolysis results in a pathological
decline of the functional content of complex I.
Genetic and functional analysis of mitochondria in the case of the
familiar PD associated with the W437X PINK1 mutation revealed that
co-segregation of mutations in the ND5 and ND6mitochondrial genes
of complex I had an impact in determining the development and the
clinical course of the disease. This ﬁnding underscores the importance
of mutational analysis of mitochondrial DNA in patients with hetero-
or homozygous familial forms of Parkinsonism as well as in sporadic
PD. Identiﬁcation of mtDNA mutations in PD could contribute to
develop therapeutical measures for preventing the progress of this
disease.
The features of the hereditary complex I dysfunctions described,
besides clarifying the molecular basis of the pathogenetic mecha-
nism of the associated neurological disorders, can shed light on
the involvement of complex I dysfunction in sporadic neurological
diseases, cancer and aging.
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